Top Page
Ascletis Pharma, Inc.
(1672)
Ascletis Pharma, Inc. (1672) vs. iShares MSCI Hong Kong ETF (EWH)
Ascletis Pharma, Inc. Business Overview & Revenue Model
Ascletis Pharma, Inc. Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.28M | 56.60M | 54.09M | 76.88M | 35.00M |
| Gross Profit | 735.00K | 25.99M | -24.69M | 39.17M | -23.50M |
| EBITDA | -390.58M | -126.09M | -284.50M | -169.35M | -181.94M |
| Net Income | -300.94M | -144.72M | -366.71M | -202.14M | -262.05M |
Balance Sheet | |||||
| Total Assets | 2.12B | 2.49B | 2.66B | 2.83B | 3.07B |
| Cash, Cash Equivalents and Short-Term Investments | 1.95B | 2.30B | 2.48B | 2.50B | 2.71B |
| Total Debt | 7.63M | 8.42M | 4.24M | 2.75M | 1.59M |
| Total Liabilities | 158.41M | 148.94M | 117.16M | 100.89M | 85.42M |
| Stockholders Equity | 1.97B | 2.34B | 2.54B | 2.73B | 2.98B |
Cash Flow | |||||
| Free Cash Flow | -343.73M | -163.32M | -156.85M | -154.13M | -123.87M |
| Operating Cash Flow | -341.58M | -144.16M | -142.45M | -146.93M | -84.91M |
| Investing Cash Flow | 978.91M | 149.84M | -1.30B | -274.49M | 132.30M |
| Financing Cash Flow | -103.51M | -81.50M | -1.42M | -31.10M | -21.67M |
Ascletis Pharma, Inc. Technical Analysis
Ascletis Pharma, Inc. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | 42.18B | 47.39 | 27.23% | ― | 2.57% | 18.79% | |
57 Neutral | 14.22B | -67.94 | -58.53% | ― | 240.05% | -140.09% | |
53 Neutral | 12.13B | -21.18 | 0.00% | ― | 1219.19% | 25.15% | |
46 Neutral | HK$10.67B | ― | -12.74% | ― | -76.58% | -4.90% | |
41 Neutral | 3.64B | -5.16 | -106.25% | ― | 0.00% | -18.99% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Ascletis Pharma, Inc. Corporate Events
Ascletis Pharma Inc. announced a voluntary lock-up undertaking by its controlling shareholders, Dr. Jinzi Jason Wu and Mrs. Judy Hejingdao Wu, who have committed not to dispose of their shares until the completion of key clinical studies. This move reflects their confidence in the company’s long-term prospects and aims to reassure investors about the company’s future developments in obesity treatment. The lock-up involves 575,952,078 shares, representing approximately 58.03% of the company’s total shares, and is linked to the outcomes of clinical trials expected by the end of 2025.
The most recent analyst rating on (HK:1672) stock is a Buy with a HK$32.00 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. has announced the successful demonstration of an ultra-long-acting subcutaneous depot maintenance formulation of its small molecule GLP-1 receptor agonist, ASC30, which showed a 75-day observed half-life in a U.S. Phase Ib study involving participants with obesity. This advancement supports once-quarterly administration, addressing a significant unmet need for maintenance therapy in chronic weight management. The formulation demonstrated favorable tolerability with minimal gastrointestinal side effects, potentially enhancing patient compliance and quality of life.
The most recent analyst rating on (HK:1672) stock is a Buy with a HK$32.00 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. announced that it will present the results of its 28-day multiple ascending dose study of ASC30, an oral small molecule GLP-1 receptor agonist, at the European Association for the Study of Diabetes Annual Meeting in Vienna. The study demonstrated superior weight loss in participants with obesity, positioning ASC30 as a potentially differentiated treatment option. The company is on track to report topline data from a Phase IIa clinical study in the fourth quarter of 2025, which could enhance its market position in obesity treatment.
The most recent analyst rating on (HK:1672) stock is a Buy with a HK$32.00 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. announced promising results from its U.S. Phase Ib study of the ASC30 oral once-daily tablet, which showed significantly higher drug exposure compared to orforglipron, a competing treatment. This higher exposure is linked to greater weight loss in participants with obesity, positioning ASC30 as a potentially competitive treatment. The study also highlighted ASC30’s favorable safety and tolerability profile, with no serious adverse events reported, suggesting its potential as a differentiated option in the obesity treatment market.
The most recent analyst rating on (HK:1672) stock is a Buy with a HK$32.00 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma, Inc. announced the completion of a placing and subscription of shares, raising approximately HK$467.69 million in net proceeds. The funds are primarily earmarked for advancing the company’s drug candidates into clinical trials for obesity, with a small portion allocated for general corporate purposes. This strategic move is expected to bolster Ascletis Pharma’s R&D capabilities and strengthen its market position.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$14.75 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma, Inc. announced a placing and top-up subscription agreement involving the sale of 52,400,000 existing shares and the issuance of 28,820,000 new shares. The transaction is expected to raise approximately HK$467.69 million in net proceeds, which will be primarily used for advancing clinical trials for obesity treatments and general corporate purposes. This strategic move is aimed at strengthening the company’s financial position and supporting its R&D initiatives, although it will result in a slight reduction of the controlling shareholders’ stake in the company.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$3.94 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. announced promising preclinical results for its obesity treatment drug candidates, ASC47 and ASC31, demonstrating significant weight loss in an animal model. The combination of these drugs showed a 44.8% reduction in body weight, outperforming a similar combination with tirzepatide, indicating potential differentiation in the obesity treatment market.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$3.94 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. announced its unaudited interim results for the six months ending June 30, 2025, highlighting a significant reduction in losses by 32.5% compared to the previous year, despite increased R&D costs. The company made notable progress in its metabolic disease pipeline, including advancements in obesity and acne treatments, underscoring its strong R&D capabilities and commitment to addressing unmet clinical needs. Ascletis has sufficient cash reserves to support its operations and research activities until 2029.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$3.94 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.